2nd Quarter - Report

OTSUKA AMERICA PHARMACEUTICAL, INC. for OTSUKA AMERICA PHARMACEUTICAL, INC.

Firm
Client
Income
—
Expenses
$340,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Medical Innovation

LobbyistCovered position, as disclosed
ORKIDEH MALKOC —

Contacted: Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; SENATE; Nuclear Regulatory Commission (NRC); Health & Human Services, Dept of (HHS)

Health Issues HCR

ADPKD (Autosomal dominant polycystic kidney disease); H.R.6082 OVERDOSE PREVENTION AND PATIENT SAFETY ACT - 42 CFR Part 2 - Federal confidentiality law and regulations; Health Care issuses as it relates to TBI (Traumatic Brain Injuries) Clinical Trials

LobbyistCovered position, as disclosed
ORKIDEH MALKOC —
MOLLY RYAN —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); Nuclear Regulatory Commission (NRC); SENATE

Bills named: H.R. 6082 (115th)

Affiliated organisations

OrganisationLocation
AVANIR PHARMACEUTICALS Aliso Viejo, CA, US

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.